No settlement: Trial begins for Lilly's cancer drug Alimta, vitamin dosing patent
This article was originally published in Scrip
Executive Summary
Eli Lilly executives telegraphed a few weeks ago that they had little interest in settling a patent lawsuit involving the lung cancer drug Alimta. With that foreshadowing, the trial began this week in a US court in Indiana where the big drug maker is based.